For all of the quality care it delivers, the U.S. health care system is one of the most dysfunctional sectors of the U.S. economy. The government spends nearly 50 cents of every dollar spent on health care, most consumers are almost entirely insulated from the cost of their decisions, and employers decide what kind of health insurance their employees get.
But while the U.S. health care system begs for reform, the Patient Protection and Affordable Care Act only exacerbates all of the current problems, promising to devolve into a price-controlled system rationed and micromanaged by bureaucrats.
IPI believes there are much better options: reform the tax treatment of health insurance; remove the state and federal mandates and regulations that make coverage more expensive; pass medical liability reform; and promote policies that create value-conscious shoppers in the health care marketplace.
Immigrants may currently be a net asset to the economy, but under the Democratic presidential candidates' proposals they will surely be a net cost.
The HHS proposed reform would do Medicare patients more harm than good. Price controls may save the government money in the short term, but they would slow the rate of medical progress.
Louisiana lawmakers are pushing forward several bills in response to an audit of the state’s Medicaid program which resulted in the removal of 30,000 people from rolls because they earned too much money. Merrill Matthews says Louisiana is doing the right thing by trying to clean up its Medicaid rolls, starting with audits.
Merrill Matthews says GOP state legislators in Louisiana and elsewhere haven't learned a thing from the Obamacare disaster.
We agree that health care needs price transparency, and it will come if and when health care consumers, rather than government, demand it.
President Obama boasted he wanted to increase individuals' access to affordable health coverage. President Trump may have just accomplished Obama's goal.
Senators John Cornyn and Richard Blumenthal want to control prescription drug prices by empowering bureaucracy. When has that ever worked?
“From a political standpoint, it is foolish to push importation. If deaths occur, the politician who promoted it will take the blame,” said Merrill Matthews, a resident scholar with the Institute for Policy Innovation.
Sen. John Cornyn's legislation that attempts to address problems he sees with the patent protections afforded to American drug companies overreaches and would limit the ability of pharmaceutical firms to develop and improve medicines.
A new Health and Human Services rule requiring pharmaceutical companies to disclose list prices for medications in commercial advertisements is unlikely to boost price transparency for consumers. In fact, it may create even more confusion.